Toad Venom Antiproliferative Activities on Metastatic Melanoma: Bio-Guided Fractionation and Screening of the Compounds of Two Different Venoms.

bufalin cardiotonic steroids high performance liquid chromatography marinobufagenin mass spectrometry melanoma resistance to drugs sodium pump targeted therapies toad venom

Journal

Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988

Informations de publication

Date de publication:
10 Aug 2020
Historique:
received: 23 06 2020
revised: 29 07 2020
accepted: 07 08 2020
entrez: 14 8 2020
pubmed: 14 8 2020
medline: 14 8 2020
Statut: epublish

Résumé

Melanoma is the most common cancer in young adults, with a constantly increasing incidence. Metastatic melanoma is a very aggressive cancer with a 5-year survival rate of about 22-25%. This is, in most cases, due to a lack of therapies which are effective on the long term. Hence, it is crucial to find new therapeutic agents to increase patient survival. Toad venoms are a rich source of potentially pharmaceutically active compounds and studies have highlighted their possible effect on cancer cells. We focused on the venoms of two different toad species:

Identifiants

pubmed: 32785105
pii: biology9080218
doi: 10.3390/biology9080218
pmc: PMC7464305
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Toxicon. 2016 Feb;110:27-34
pubmed: 26615828
Cancer Cell Int. 2019 Apr 11;19:92
pubmed: 31011289
Steroids. 2019 Dec;152:108490
pubmed: 31499071
Physiology (Bethesda). 2004 Dec;19:377-87
pubmed: 15546856
An Acad Bras Cienc. 2005 Mar;77(1):33-43
pubmed: 15692677
Life Sci. 1992;51(1):17-24
pubmed: 1614270
Evid Based Complement Alternat Med. 2012;2012:591241
pubmed: 22719785
Toxicon. 2013 Sep;72:43-51
pubmed: 23796725
Tumour Biol. 2014 May;35(5):4885-90
pubmed: 24570183
Med Res Rev. 2017 Jan;37(1):98-148
pubmed: 27569556
Oncology (Williston Park). 2017 Nov 15;31(11):e23-e32
pubmed: 29179253
J Ethnopharmacol. 2014 Mar 14;152(2):372-6
pubmed: 24491644
Drug Chem Toxicol. 2019 Jul;42(4):444-450
pubmed: 30777466
Am J Transl Res. 2015 Jan 15;7(1):1-14
pubmed: 25755824
Development. 2015 Apr 1;142(7):1387
pubmed: 25804742
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Oncotarget. 2018 Feb 9;9(17):13783-13795
pubmed: 29568394
Circ Heart Fail. 2015 Nov;8(6):1068-76
pubmed: 26276886
J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Nov 15;859(2):157-63
pubmed: 17928276
Crit Rev Oncol Hematol. 2016 Feb;98:242-53
pubmed: 26616525
Biochim Biophys Acta. 2007 Sep;1776(1):32-57
pubmed: 17706876
J Sep Sci. 2019 Apr;42(7):1384-1392
pubmed: 30667156
Cytotechnology. 2010 Dec;62(6):573-83
pubmed: 20963488
World J Biol Chem. 2015 May 26;6(2):28-33
pubmed: 26009701
J Ethnopharmacol. 2010 Sep 15;131(2):368-76
pubmed: 20637273
Toxicon. 2019 Feb;158:63-68
pubmed: 30529380
Cancer Prev Res (Phila). 2019 Oct;12(10):653-666
pubmed: 31431500
Carcinogenesis. 2018 May 3;39(5):700-707
pubmed: 29546393
Biol Rev Camb Philos Soc. 1997 Aug;72(3):365-79
pubmed: 9336100
Toxicol Lett. 2018 Mar 15;285:121-131
pubmed: 29287997
Pharmacol Rev. 2009 Mar;61(1):9-38
pubmed: 19325075
Invest New Drugs. 2013 Aug;31(4):1087-94
pubmed: 23748872
Science. 2014 Nov 21;346(6212):945-9
pubmed: 25414302
J Nat Prod. 2013 Jun 28;76(6):1078-84
pubmed: 23706005
Oncol Lett. 2017 Jul;14(1):15-22
pubmed: 28693129
Cell Biol Toxicol. 2019 Dec;35(6):521-539
pubmed: 30739221
Biomed Res Int. 2019 Feb 21;2019:2492315
pubmed: 31214612
Talanta. 2018 Sep 1;187:193-199
pubmed: 29853035
Phytochemistry. 1998 May;48(1):1-29
pubmed: 9621450
Eur J Pharmacol. 2019 Sep 5;858:172472
pubmed: 31228447
Hypertension. 2000 Sep;36(3):442-8
pubmed: 10988279
J Pharm Biomed Anal. 2011 Sep 10;56(2):210-20
pubmed: 21696903
Am J Perinatol. 2012 Nov;29(10):777-85
pubmed: 22814872
Biomed Chromatogr. 2013 Jun;27(6):685-7
pubmed: 23319165
J Ethnopharmacol. 2019 Oct 5;242:112049
pubmed: 31265888
Toxicon. 1987;25(10):1023-95
pubmed: 3321567
Toxicon. 2017 Mar 1;127:63-76
pubmed: 28069354
Pharmaceuticals (Basel). 2010 Mar 29;3(4):940-960
pubmed: 27713283
Biology (Basel). 2014 Feb 13;3(1):139-56
pubmed: 24833338
Front Oncol. 2020 Jan 23;9:1572
pubmed: 32039033
J Ethnopharmacol. 2017 Feb 23;198:235-254
pubmed: 28034659
Eur J Cancer. 2017 Mar;73:85-92
pubmed: 28169047
Rapid Commun Mass Spectrom. 2010 Mar 15;24(5):667-78
pubmed: 20155762
J Cell Mol Med. 2009 Sep;13(9B):3960-72
pubmed: 19243476
Nature. 2017 May 11;545(7653):175-180
pubmed: 28467829
Toxicon. 2016 Oct;121:119-129
pubmed: 27616454

Auteurs

Laura Soumoy (L)

Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and Pharmacy, University of Mons, 7000 Mons, Belgium.

Mathilde Wells (M)

Laboratory of Pharmaceutical Analysis, Faculty of Medicine and Pharmacy, University of Mons, 7000 Mons, Belgium.

Ahmad Najem (A)

Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet (ULB), 1000 Brussels, Belgium.

Mohammad Krayem (M)

Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet (ULB), 1000 Brussels, Belgium.

Ghanem Ghanem (G)

Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet (ULB), 1000 Brussels, Belgium.

Stéphanie Hambye (S)

Laboratory of Pharmaceutical Analysis, Faculty of Medicine and Pharmacy, University of Mons, 7000 Mons, Belgium.

Sven Saussez (S)

Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and Pharmacy, University of Mons, 7000 Mons, Belgium.
Department of Oto-Rhino-Laryngology, Université Libre de Bruxelles (ULB), CHU Saint-Pierre, 1000 Brussels, Belgium.

Bertrand Blankert (B)

Laboratory of Pharmaceutical Analysis, Faculty of Medicine and Pharmacy, University of Mons, 7000 Mons, Belgium.

Fabrice Journe (F)

Laboratory of Human Anatomy and Experimental Oncology, Faculty of Medicine and Pharmacy, University of Mons, 7000 Mons, Belgium.
Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet (ULB), 1000 Brussels, Belgium.

Classifications MeSH